Emily Kopp, Web Producer at Kaiser Health News, most recently worked as a freelance reporter. She has previously worked at Politico and AIS Health. Before that, she interned with the Center for Responsive Politics.
Emily Kopp
From this contributor
Nonprofit with ties to pharma launches campaign against drug imports
Both the Pharmaceutical Research and Manufacturers of America and the nonprofit group have gone to great lengths to show that drugmakers are not driving what they describe as a “grass-roots” effort to fight imports.
Nonprofit with ties to pharma launches campaign against drug imports
Senators want answers about reported probe of U.S. health secretary
Nine U.S. senators are pushing the U.S. Attorney General to reveal what he knows about a reported investigation into Tom Price’s stock trades that a top federal prosecutor might have begun before being fired by the Trump administration.
Senators want answers about reported probe of U.S. health secretary
Most patient advocacy groups accept funding from pharma
At least 83 percent of the United States' largest patient advocacy groups take contributions from the drug industry, and not all of them are transparent about it.
Most patient advocacy groups accept funding from pharma
Explore more from The Transmitter
From friend to foe: How the brain updates feelings toward others
A specific hippocampus-to-amygdala pathway reassigns emotional valence to a known individual, whereas the hippocampus’s own representation of that individual’s identity remains stable.
From friend to foe: How the brain updates feelings toward others
A specific hippocampus-to-amygdala pathway reassigns emotional valence to a known individual, whereas the hippocampus’s own representation of that individual’s identity remains stable.
Mass-produced science is coming. What happens to scientists?
Artificial intelligence may soon enable researchers to generate high-quality science at a previously unimaginable speed. For science consumers—the public, medical patients, technology users—the likely effects will be positive. For scientists, the effects will be as disruptive as industrial mass production was for artisan manufacturers.
Mass-produced science is coming. What happens to scientists?
Artificial intelligence may soon enable researchers to generate high-quality science at a previously unimaginable speed. For science consumers—the public, medical patients, technology users—the likely effects will be positive. For scientists, the effects will be as disruptive as industrial mass production was for artisan manufacturers.
Neuropathologist not guilty of research misconduct, says university probe
The investigation determined that seven papers by corresponding author Adriano Aguzzi have “scientifically significant” errors, which Aguzzi attributes to his former students.
Neuropathologist not guilty of research misconduct, says university probe
The investigation determined that seven papers by corresponding author Adriano Aguzzi have “scientifically significant” errors, which Aguzzi attributes to his former students.